The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.
ARV/ART
News
November 9, 2020
eLearning course
August 27, 2020
The National Department of Health is introducing a new drug, Dolutegravir (DTG), in combination with Tenofovir (TDF) and Lamivudine (3TC). The combination of TDF/3TC/DTG is known as TLD. The objectives of this training are to:
Resource
July 23, 2020
Resource
July 14, 2020
Introduction
Resource
July 6, 2020
Introduction
Few studies have systematically described population‐level differences comparing men and women across the continuum of routine HIV care.
Resource
June 30, 2020
Background
Resource
June 29, 2020
Introduction
News
June 25, 2020
UNAIDS study shows that the impact on production and logistics caused by COVID-19 could have a significant effect on antiretroviral therapy supply worldwide, but steps taken now could lessen the damage done
Resource
June 18, 2020
Introduction
South Africa introduced Universal Test and Treat in 2016 including antiretroviral therapy (ART) initiation on the same‐day as HIV diagnosis.
Resource
June 17, 2020
Darunavir/ritonavir administered with rifampicin causes hepatotoxicities in people living with HIV, according to results of a study led by researchers at the department of medicine, the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa) and the Desm
